Identifying potential adverse effects by patients' ratings: a proof-of-concept study of a novel approach.

OBJECTIVE Methods to evaluate adverse effects of medications are significantly underdeveloped compared to those for efficacy. In this pilot proof-of-concept study, we preliminarily compared a novel approach-the Symptom Assessment Tool (SAT)-to a systematic and detailed assessment by a physician for identifying symptoms that were potentially adverse effects (sensitivity) and excluding symptoms that were unlikely to be adverse effects (specificity). METHODS A symptom inventory and rating of symptom severity were completed before starting a psychotropic medication (or increasing its dose), and again 2 weeks later. Each symptom was systematically assessed by the patient-rated SAT and by a physician and was classified as either a potential or unlikely adverse effect. The primary analysis compared the classification of symptoms by the SAT to that by the physician. Potential adverse effects were also subcategorized as possible or probable adverse effects. RESULTS A sample of 193 symptoms from 15 adults was evaluated, only 37.3% of which were considered potential adverse effects by the physician. Sensitivity of the SAT compared to physician's assessment was 90.3% for potential adverse effects and 97.5% for the subgroup of probable adverse effects. The SAT correctly identified 63.6% of the symptoms as unlikely adverse effects (specificity), and its negative predictive value was 91.7%. CONCLUSIONS The SAT, appropriate for its intended use as a screening tool, had high sensitivity and moderate specificity and could present physicians with a limited number of potential adverse effects for further assessment and intervention. Further evaluation and refinement of this approach is warranted.

[1]  J. McCracken,et al.  Review of safety assessment methods used in pediatric psychopharmacology. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

[2]  L. Markson,et al.  Discontinuation of use and switching of antidepressants: influence of patient-physician communication. , 2002, JAMA.

[3]  S. Roose Compliance: the impact of adverse events and tolerability on the physician’s treatment decisions , 2003, European Neuropsychopharmacology.

[4]  J. Levine,et al.  General versus specific inquiry with SAFTEE. , 1992, Journal of clinical psychopharmacology.

[5]  R. Bentall,et al.  A Self-Rating Scale for Measuring Neuroleptic Side-Effects , 1995, British Journal of Psychiatry.

[6]  J. Levine,et al.  SAFTEE: a technique for the systematic assessment of side effects in clinical trials. , 1986, Psychopharmacology bulletin.

[7]  M. Posternak,et al.  Which factors influence psychiatrists' selection of antidepressants? , 2004, The American journal of psychiatry.

[8]  E. Lindström,et al.  Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat) , 2001, Nordic journal of psychiatry.

[9]  U. Ahlfors,et al.  The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients , 1987, Acta psychiatrica Scandinavica. Supplementum.

[10]  D. Kupfer,et al.  Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. , 2004, Controlled clinical trials.

[11]  R. Huupponen,et al.  Adverse drug effects in elderly people – a disparity between clinical examination and adverse effects self-reported by the patient , 2007, European Journal of Clinical Pharmacology.

[12]  J. Levine,et al.  Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[13]  D. Greenblatt,et al.  A method for estimating the probability of adverse drug reactions , 1981, Clinical pharmacology and therapeutics.